Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 7746
IPSCIO Record ID: 5425
IPSCIO Record ID: 222558
For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.
For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.
For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.
Product means any Agreement Product or Licensees Product.
Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.
Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.
Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.
Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'
IPSCIO Record ID: 3964
The Compass Array Library is a diverse subset of approximately 25,000 compounds that have computationally selected to represent at least 12.5% of the Mapping Array Libraries to be generated during 2000 and 2001.
ArQule will provide approximately 1mg of each Compass Array compound dissolved in 250 (mu)L of 100% DMSO (10 mM). The compounds will be provided in 96-well plates with 80 filled wells per plate. Because ArQule performs 25% quality control analysis of each Mapping Array Library corresponding to the Compass Array Library, the purity and confirmation of molecular weight is similar to the Mapping Array Library, as described below. A Markush structure file defining each chemical theme is supplied with every shipment.
2. Mapping Array Libraries.
The Mapping Array repository is a diverse screening library. The Mapping Array Libraries produced in the year 2000 contain approximately 200,000 compounds. The Mapping Array Libraries planned for production in the year 2001 will contain approximately 200,000 compounds.
ArQule will provide 1 mg of each Mapping Array compound dissolved in 250(mu)L of 10mM 100% DMSO. The compounds will be provided in 96-well plates with up to 80 filled wells per plate. ArQule performs 25% quality control analysis of each Mapping Array Library by HPLC/UV/ELSD for purity and flow injection mass spectrometry for confirmation of molecular weight. Each Mapping Array Library is on average more than 85% pure as determined by HPLC analysis. A Markush structure file defining each chemical theme is supplied with every shipment.
3. Confirmation Samples and Resynthesized Compounds.
As determined by the Research Committee, ArQule shall resynthesize and deliver to Sankyo approximately five (5) mg of any Available Compound to enable Sankyo to conduct screening activities in accordance with Subsection 3.2. ArQule will resynthesize up to fifteen (15) compounds per quarter (60 annually), subject to payments described in Section 8.1.3. ArQule will provide each resynthesized compound as a dry solid, power or oil with a purity of 95% based on HPLC/UV, ELSD.
4. Directed Array Compounds.
Unless otherwise agreed to by the Research Committee, all ArQule Compounds delivered as part of the Directed Arrays will be provided 30 mmol of compound in DMSO in 96-well plates with up to 80 filled wells per plate. ArQule performs 100% quality control analysis of each Directed Array compound tested by HPLC/UV/ELSD. The average purity of each compound is 85% as determined by HPLC analysis. An SD file is supplied with every shipment.
'Derivative Compoundâ€ shall mean a Derivative Compound developed from a Licensed Compound in the course of an optimization program for the molecular Target or other Target (e.g., whole cell screen) against which such Licensed Compound was initially discovered to have biological activity. â€œCompass Array Libraryâ€ shall mean a collection of Licensor Compounds that is a diverse representative subset of the Mapping Array Libraries used for initial screening of the Mapping Array Libraries.